LON:FAB Fusion Antibodies Share Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fusion Antibodies PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 197.50 +15.00 (+8.22 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range 140Now: GBX 197.50▼ 20550-Day Range 80MA: GBX 95.53▼ 182.5052-Week Range 55Now: GBX 197.50▼ 230Volume462,941 shsAverage Volume35,274 shsMarket Capitalization£50.24 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartCompetitorsInsider TradesHeadlines Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases. The company offers antibody identification and discovery services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of monoclonal antibodies. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and stable cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies worldwide. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Fusion Antibodies. Previous Next 2.6 Community Rank Outperform VotesFusion Antibodies has received 54 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFusion Antibodies has received 51 “underperform” votes. (Add your “underperform” vote.)Community SentimentFusion Antibodies has received 51.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fusion Antibodies and other stocks. Vote “Outperform” if you believe FAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FAB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFusion Antibodies does not currently pay a dividend.Dividend GrowthFusion Antibodies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fusion Antibodies insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Fusion Antibodies is -61.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fusion Antibodies is -61.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFusion Antibodies has a P/B Ratio of 9.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:FAB Previous Symbol CUSIPN/A CIKN/A Webfusionantibodies.com Phone+44-28-90432800Debt Debt-to-Equity Ratio7.90 Current Ratio2.83 Quick Ratio2.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£3.90 million Price / Sales12.90 Cash FlowGBX 16.26 per share Price / Cash Flow12.14 Book ValueGBX 21.80 per share Price / Book9.06Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees22 Outstanding Shares25,437,000Market Cap£50.24 million Next Earnings DateN/A OptionableNot Optionable GBX 197.50 +15.00 (+8.22 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FAB News and Ratings via Email Sign-up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Fusion Antibodies (LON:FAB) Frequently Asked Questions How has Fusion Antibodies' stock been impacted by Coronavirus (COVID-19)? Fusion Antibodies' stock was trading at GBX 67.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FAB shares have increased by 192.6% and is now trading at GBX 197.50. View which stocks have been most impacted by COVID-19. Who are some of Fusion Antibodies' key competitors? Some companies that are related to Fusion Antibodies include Medicenna Therapeutics (MDNA), Bioventix (BVXP), 4d Pharma (DDDD), Ampio Pharmaceuticals (AMPE), Ampio Pharmaceuticals (AMPE), Faron Pharmaceuticals Oy (FARN), BELLUS Health (BLU), CorMedix (CRMD), CorMedix (CRMD), Enochian Biosciences (ENOB), Exicure (XCUR), Exicure (XCUR), Matinas BioPharma (MTNB), Matinas Biopharma (MTNB) and Horizon Discovery Group (HZD). View all competitors. What other stocks do shareholders of Fusion Antibodies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Antibodies investors own include Aminex (AEX), D4t4 Solutions (D4T4), Snap-on (SNA), Asian Television Network International (SAT), Lockheed Martin (LMT), Blockchain Worldwide (BLOC) and ABM Industries (ABM). Who are Fusion Antibodies' key executives? Fusion Antibodies' management team includes the following people: Dr. Paul Gerard Kerr, CEO & Director (Age 47)Mr. James Fair, CFO, Company Sec. & Director (Age 53)Dr. Richard John Buick, CTO & Director (Age 42)Prof. Jim Johnston, Founder What is Fusion Antibodies' stock symbol? Fusion Antibodies trades on the London Stock Exchange (LON) under the ticker symbol "FAB." How do I buy shares of Fusion Antibodies? Shares of FAB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Fusion Antibodies' stock price today? One share of FAB stock can currently be purchased for approximately GBX 197.50. How big of a company is Fusion Antibodies? Fusion Antibodies has a market capitalization of £50.24 million and generates £3.90 million in revenue each year. Fusion Antibodies employs 22 workers across the globe. What is Fusion Antibodies' official website? The official website for Fusion Antibodies is fusionantibodies.com. How can I contact Fusion Antibodies? Fusion Antibodies' mailing address is Springbank Industrial Estate 1 Springbank Road, BELFAST, NIR BT17 0QL, United Kingdom. The company can be reached via phone at +44-28-90432800. This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
